Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tagrisso+Orpathys improved PFS & OS in EGFRm lung

August 17, 2026

Datroway approved in EU for TNBC

July 31, 2026

AstraZeneca results: H1 and Q2 2026

July 27, 2026

Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

July 27, 2026

Update on Ultomiris Phase III trial in HSCT-TMA

July 27, 2026

Sone-Ve improved survival in gastric cancers

July 27, 2026

Half-year Financial Report

July 27, 2026

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

July 24, 2026

Etcamah approved in the EU for ER+ breast cancer

July 23, 2026

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

July 14, 2026

AstraZeneca licenses novel EGFR inhibitor

July 14, 2026

Update on CARDIO-TTRansform Phase III trial

July 9, 2026

Admission of Further Securities to Trading

July 1, 2026

Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours

June 29, 2026

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

June 29, 2026

Enhertu approved in EU for HER2+ solid tumours

June 29, 2026

Datroway recommended for approval in EU for TNBC

June 29, 2026

Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial

June 28, 2026

Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

June 26, 2026

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

June 24, 2026

AstraZeneca Joins ZERO Prostate Cancer's Historic 'Blitz the Barriers' Initiative as a Founding Partner

June 15, 2026

Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

June 15, 2026

Truqap approved in US for prostate cancer

June 15, 2026

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

June 12, 2026

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio

June 8, 2026

Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026

June 1, 2026

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

June 1, 2026

Imfinzi approved in US for early bladder cancer

May 29, 2026

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026

ATTR Early-Career Research Forum Opens National Call for Abstracts; Two $100,000 Wiesman Awards to Be Granted

May 28, 2026

แอสตร้าเซนเนก้า จับมือ โรช ไดแอกโนสติกส์ เอเชีย แปซิฟิก เร่งสร้างระบบนิเวศด้านพยาธิวิทยาขั้นสูงสำหรับมะเร็งเต้านมและมะเร็งปอด อย่างยั่งยืน

May 28, 2026

US FDA decision date on camizestrant extended

May 27, 2026

Enhertu recommended in EU for HER2+ solid tumours

May 26, 2026

Datroway approved in US for 1L triple-negative BC

May 26, 2026

Camizestrant recommended for breast cancer in EU

May 26, 2026

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026

Enhertu approved in two HER2+ early BC settings

May 18, 2026

Baxfendy approved in the US for hypertension

May 18, 2026

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

May 18, 2026

Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer

May 15, 2026

Imfinzi + EV improves EFS & OS in bladder cancer

May 14, 2026

Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial

May 12, 2026

FDA ODAC vote on camizestrant in breast cancer

May 1, 2026

FDA ODAC recommends Truqap in prostate cancer

May 1, 2026

SKF commits to a sovereign AI future through strategic partnership with Sferical AI

April 30, 2026

AstraZeneca results: Q1 2026

April 29, 2026

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

April 28, 2026

Breztri approved in the US for asthma

April 28, 2026

Saphnelo self-administration approved in the US

April 27, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.